Axon Enterprise (NASDAQ:AXON) PT Raised to $441.00

Axon Enterprise (NASDAQ:AXON) had its target price lifted by analysts at The Goldman Sachs Group from $385.00 to $441.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target would suggest a potential downside of 0.97% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Barclays boosted their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Northland Securities upped their price objective on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Craig Hallum boosted their price target on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Robert W. Baird boosted their price target on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Finally, Needham & Company LLC upped their price objective on Axon Enterprise from $400.00 to $525.00 and gave the stock a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $382.85.

Axon Enterprise Stock Down 1.0 %

Shares of NASDAQ AXON traded down $4.28 during mid-day trading on Wednesday, hitting $445.33. 73,021 shares of the stock traded hands, compared to its average volume of 519,202. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise has a 52 week low of $199.29 and a 52 week high of $455.17. The company has a market cap of $33.65 billion, a price-to-earnings ratio of 117.50, a PEG ratio of 11.74 and a beta of 0.94. The stock has a fifty day moving average price of $391.84 and a 200-day moving average price of $333.90.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The firm’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.80 earnings per share. Research analysts anticipate that Axon Enterprise will post 1.79 EPS for the current year.

Insider Buying and Selling

In related news, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total value of $318,177.00. Following the completion of the transaction, the director now owns 3,653 shares in the company, valued at $1,291,445.09. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares in the company, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $353.53, for a total value of $318,177.00. Following the sale, the director now owns 3,653 shares in the company, valued at $1,291,445.09. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 371,172 shares of company stock worth $137,000,162 in the last 90 days. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several institutional investors have recently bought and sold shares of the company. Mather Group LLC. boosted its holdings in Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after buying an additional 27 shares during the last quarter. CWM LLC boosted its holdings in shares of Axon Enterprise by 1.3% during the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 36 shares during the last quarter. SPC Financial Inc. boosted its holdings in shares of Axon Enterprise by 2.2% during the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 38 shares during the last quarter. Dorsey Wright & Associates boosted its holdings in shares of Axon Enterprise by 0.3% during the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock worth $4,135,000 after purchasing an additional 39 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 40 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.